The global zika virus testing market size is projected to register a substantial CAGR during the forecast period attributed to rising participation and involvement from national governments of low-income region and global organizations including UNICEF for public awareness of the disease.
Zika virus, as a disease, is primarily spread by mosquito bites. The disease is mainly caused by the bite of yellow fever mosquitoes, also widely known as Aedes mosquitoes, which is mostly happened during the daytime. As per the study of World Health Organization (WHO), the virus was first identified to be prevailed in monkeys in 1947, later it was discovered in humans in 1952 in Uganda. At present, the virus is active across 86 countries and territories and it is widely known that the virus does not show any severe symptoms. However, some common symptoms including fever, headache, muscle pain, and rash are considered to be associated with the disease. A person who is infected with the virus during pregnancy has higher chance of birth defects including preterm birth, fetal loss, and stillbirth as pregnancy complications. The expected time span to exposure of zika virus symptoms is three to 14 days and they usually last for two to seven days.
The health authorities in Brazil found a correlation between the virus and neurological birth defects. The highest number of microcephaly cases was recorded between 2015 and 2016 and as a result, a threat to public health was declared in October 2016 in the country. After the end of the zika epidemic in 2016, several research were conducted to develop diagnostics to identify correlation between microcephaly in newborns and the virus. A report by the US Centers for Disease Control and Prevention (CDC) stated that around 5,264 people were infected with the virus in the US, among which 1,700 were pregnant women and 58 babies were born having birth defects. One of the reasons for the virus infection as the epidemic was due to rising number of the virus transmission during travel from one country to other. Around 4,830 cases were registered as travel-related transmission cases in the US in 2016, which was approximately 94.0% of the total cases registered.
Market Trends, Drivers, Restraints, and Opportunities
- Advancement of technologies in diagnostic tests and increase in RD by pharmaceutical companies are prominent factors driving the market growth.
- Development of point of care diagnostic kits that can provide quick and accurate results, easy to use, and are cost-effective are expected to push the market growth significantly.
- Active participation from global major organizations such as UNICEF, WHO, and others along with their wide focus on preventive measures for economic and social impact of the virus outbreak worldwide present a major driver for market growth.
- Incorporation of blood screening as an addition for zika virus diagnosis in order to prevent transmission is another key driver of the market.
- Lack of healthcare infrastructure and absence of concrete framework for the virus treatment pose major challenges that can hinder the market expansion.
Scope of the Report
The report on the global zika virus testing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Zika Virus Testing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Test Types (Serological Testing and Nucleic Acid Amplification Testing)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Roche; Quest Diagnostics, Inc.; Hologic, Inc.; Chembio Diagnostic Systems, Inc.; SD Biosensors, Inc.; Biocan Diagnostics; and Chembio Diagnostics, Inc.
Market Segment Insights
Serological testing segment is projected to constitute a major share
On the basis of test types, the market is bifurcated into serological testing and nucleic acid amplification testing. Both of the serological testing and nucleic acid amplification testing held approximately equal market share in 2020 as these testing are widely used and commercially successful to perform tests to detect the virus. However, the nucleic acid amplification testing segment is expected to hold a key market share in the coming years owing to be cost-effective, easily available, and can be used for mass surveillance.
On the other hand, the serological testing is expected to constitute a major share during the forecast period as they are preferred over nucleic acid amplification testing owing to provide rapid results and can acutely detect the last stage of the virus development.
North America is anticipated to expand at a considerable CAGR
In terms of regions, the global zika virus testing market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to expand at a considerable CAGR during the projected period owing to strict regulations for the adoption of the virus testing from regulatory bodies as well as extensive conduct of research activities for the development of better diagnostic and treatment equipment. During the outbreak of the epidemic in 2016, various regulatory frameworks were strictly implemented by collaborating with various global organizations including PAHO, WHO, and CDC to prevent the widespread of the virus especially in the US. It was declared mandatory for North American citizens to undergo nucleic acid amplification testing by donating blood. This factor plays a crucial role that push the growth of the regional market at a large extent.
On the other hand, the market of Latin America is anticipated to register a health growth rate during the forecast period owing to wide prevalence of the disease in many countries of the region and several governments’ initiatives for implementing preventive measures. In 2016, the region had recorded the second highest number of the disease cases, representing more than 50% of the global figure. During the time period of four months from October 2015 to January 2016, more than 4,000 cases were registered with microphelacy in newborns in Brazil; as a result, Brazil’s National Development Bank (BNDES) announced a funding of USD 136.6 million in March 2016 to fight various the illness associated with the virus. This was a leading factor that helped to boost the growth of the regional market.
Segments Covered in the Report
The global zika virus testing market has been segmented on the basis of
- Serological Testing
- Nucleic Acid Amplification Testing
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- Quest Diagnostics, Inc.
- Hologic, Inc.
- Chembio Diagnostic Systems, Inc.
- SD Biosensors, Inc.
- Biocan Diagnostics
- Chembio Diagnostics, Inc.
Key players competing in the global zika virus testing market include Roche; Quest Diagnostics, Inc.; Hologic, Inc.; Chembio Diagnostic Systems, Inc.; SD Biosensors, Inc.; Biocan Diagnostics; and Chembio Diagnostics, Inc. Many of these players have adopted business strategies such as improvement in diagnostic products and products approved from the US FDA-EUA to increase their market position and expand their consumer base globally.